Loss of Bone Marrow Mesenchymal Stem Cells in Myeloproliferative Neoplasms as an Indicator of Niche Dysregulation
Bishop E. et al, (2016), JOURNAL OF PATHOLOGY, 240, 23 - 23
EMBRYONIC THYMOPOIESIS IS INITIATED BY AN IMMUNE-RESTRICTED LYMPHO-MYELOID PROGENITOR INDEPENDENTLY OF NOTCH SIGNALING
Luis TC. et al, (2016), EXPERIMENTAL HEMATOLOGY, 44, S65 - S65
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.
Quek L. et al, (2016), The Journal of experimental medicine, 213, 1513 - 1535
Distinct myeloid progenitor differentiation pathways identified through single cell RNA sequencing
Nerlov C. et al, (2016), Nature Immunology
RUXOLITINIB COMPARED WITH BEST AVAILABLE THERAPY FOR ESSENTIAL THROMBOCYTHAEMIA PATIENTS RESISTANT OR INTOLERANT TO HYDROXYCARBAMIDE IN MAJIC - AN INVESTIGATOR LEAD RANDOMIZED TRIAL
Harrison C. et al, (2016), HAEMATOLOGICA, 101, 97 - 97
SINGLE-CELL PROFILING OF HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITORS IDENTIFIES DISTINCT MEGAKARYOCYTE AND ERYTHROID DIFFERENTIATION PATHWAYS
Psaila B. et al, (2016), HAEMATOLOGICA, 101, 21 - 21
Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways
Psaila B. et al, (2016), Genome Biology
Single cell RNA sequencing reveals molecular and functional platelet bias of aged hematopoietic stem cells
Nerlov C. et al, (2016), Nature Communications
A dynamic niche provides Kit ligand in a stage-specific manner to the earliest thymocyte progenitors
Buono M. et al, (2016), Nature Cell Biology
Ezh2 and Runx1 Mutations Targeted to Early Lymphoid Progenitors Collaborate to Promote Early Thymic Progenitor Leukemia
Booth C. et al, (2015), BLOOD, 126
Single Cell Whole Transcriptome Analysis Reveals Distinct Molecular Signatures of Therapy-Resistant Chronic Myeloid Leukemia Stem Cells
Giustacchini A. et al, (2015), BLOOD, 126
Application of single-cell genomics in cancer: promise and challenges.
Wills QF. and Mead AJ., (2015), Hum Mol Genet, 24, R74 - R84
Clinical potential of pacritinib in the treatment of myelofibrosis.
Duenas-Perez AB. and Mead AJ., (2015), Ther Adv Hematol, 6, 186 - 201
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
Mead AJ. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 170, 29 - 39
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Mead AJ. et al, (2015), Br J Haematol, 170, 29 - 39
PATIENT-REPORTED OUTCOMES (PROS) IN PERSIST-1: A RANDOMIZED, MULTI-COUNTRY PHASE III TRIAL OF THE JAK2 INHIBITOR PACRITINIB (PAC) VS. BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF)
Mesa R. et al, (2015), HAEMATOLOGICA, 100, 336 - 337
PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)
Harrison C. et al, (2015), HAEMATOLOGICA, 100, 103 - 103
PROSPECTIVE ISOLATION OF NOVEL POPULATIONS OF MEGAKARYOCYTE-AND ERYTHROID-PRIMED MEGAKARYOCYTE-ERYTHROID PROGENITORS DEMONSTRATES MEGAKARYOCYTE-BIASED LINEAGE COMMITMENT IN PRIMARY MYELOFIBROSIS
Psaila B. et al, (2015), HAEMATOLOGICA, 100, 97 - 97
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
Tapper W. et al, (2015), Nat Commun, 6